The financials
Recursion Pharmaceuticals, Inc. by the numbers
Recursion Pharmaceuticals, Inc. (RXRX) reported revenue of $6.5M in Q1 2026 (quarter ended March 31, 2026), down 56% from the same quarter a year earlier. That came with a gross margin of −93% and net loss of $118M. For the full year FY2025, revenue was $75M (+27% year on year) and net income −$645M. Its largest product in 2026-Q1 was License And Service at $6.3M, 97% of the disclosed total, just ahead of Grant at 2.6%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $6.5M | $15M | −56% |
| Gross profit | −$6.0M | −$7.1M | n/a |
| Operating income | −$129M | −$191M | n/a |
| Net income | −$118M | −$202M | n/a |
| Diluted EPS | −$0.22 | −$0.50 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License And Service | $6.3M | 97% |
| Grant | $171K | 2.6% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $6.5M (+25%)
License And Service grew -57% year on year
Segment Latestquarter on quarteryear on year
- License And Service$6.3M$6.3MQoQ +26%year on year -57%+26%-57%
- Grant$171.0K$171.0KQoQ -11%year on year --11%-